Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single Cell Minimal Residual Disease Analysis in Multiply Relapsed AML Patient

ABSTRACT: Single Cell Minimal Residual Disease Analysis in Multiply Relapsed AML Patient

PROVIDER: PRJNA1132526 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Single Cell Minimal Residual Disease Analysis in Multiply Relapsed AML Patient

Project description:This patient experienced multiple AML relapses, yet demonstrated exceptional response to the small molecule IDH1 inhibitor Olutasidenib. To further study both the disease and treatment biology specific to this patient, we used a novel single cell AML MRD assay to perform both single cell DNA and protein-level analysis.

2025-06-23 | GSE271629 | GEO

Gene expression profiles associated with pediatric relapsed AML

Project description:In high income countries 90% of the patients achieve complete remission after induction chemotherapy. However, 30-40% of these patients suffer from relapse. These patients face a dismal prognosis, as the majority (>60%) of relapsed patients die within 5 years. As a result, outcome for pediatric acute myeloid leukemia (AML) patients remains poor and has stabilized over the past 15 years. To prevent or better treat relapse of AML is the best option to improve outcome. Despite patient specific differences, most patients do respond to initial therapy. This suggests that at relapse, mechanisms are active that cause the altered response to chemotherapy. Detailed understanding of mechanisms that cause relapse remain largely elusive. To gain insight in the molecular pathways that characterize relapsed AML, we performed genome wide gene expression profiling on paired initial diagnosis and relapsed AML samples of 23 pediatric AML patients. We used pathway analysis to find which molecular pathways are involved in altered gene expression between diagnosis and relapse samples of individual AML patients. 23 paired diagnosis and relapse bone marrow or peripheral blood samples were collected and cryo-preserved. They were later thawed and processed for hybridization to Affymetrix U133 Plus 2.0 arrays.

2015-05-07 | E-GEOD-52891 | biostudies-arrayexpress

DNA methylation of Relapsed/Refractory AML

Project description:DNA methylation of Relapsed/Refractory AML

| PRJNA934390 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma

| PRJNA1014439 | ENA

Gene expression profiles associated with pediatric relapsed AML

2015-05-07 | GSE52891 | GEO

Genotyping of human AMP patients using 27 pairs of diagnostic and relapsed AML samples

Project description:Relapse is the commonest cause of death in acute myeloid leukaemia (AML), but the mechanisms leading to relapse are unclear. Recently, acquisition of segmental uniparental disomy (UPD) by mitotic recombination (MR) has been reported in 15-20% of AML samples at diagnosis using whole genome single nucleotide polymorphism (SNP) arrays. These cytogenetically invisible abnormalities are associated with homozygous mutations in several types of malignancy. Clonal evolution of heterozygous to homozygous mutations by MR could provide a mechanism for relapse. Experiment Overall Design: DNA from 27 pairs of diagnostic and relapsed AML samples were analysed using Affymetrix 10K SNP arrays. The genotype data of relapsed AML were compared with the data from the corresponding presentation AML.

2008-06-15 | E-GEOD-7210 | biostudies-arrayexpress

Towards minimal residual disease-directed therapy in melanoma

Project description:Towards minimal residual disease-directed therapy in melanoma

| PRJNA477841 | ENA

Towards minimal residual disease-directed therapy in melanoma

Project description:Many patients with advanced cancers achieve dramatic responses to a panoply of therapeutics, yet retain minimal residual disease (MRD), which ultimately results in relapse. To gain insights into the biology of MRD we applied single-cell RNA-sequencing to malignant cells isolated from BRAF-mutant patient-derived xenograft (PDX) melanoma cohorts exposed to concurrent RAF/MEK-inhibition.

2018-07-18 | GSE116237 | GEO

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vivo]

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vivo]

| PRJNA1014440 | ENA

Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

Project description:Minimal Residual Disease in Mouse Hepatocellular carcinoma [in vitro]

| PRJNA1014444 | ENA